Targeting the PDGF signaling pathway in tumor treatment

Cell Communication and Signaling

Volumn 11, Issue 1, 2013, Pages

  Heldin, Carl Henrik ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; CEDIRANIB; DASATINIB; IMATINIB; LINIFANIB; MOTESANIB; NILOTINIB; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PONATINIB; QUIZARTINIB; SORAFENIB; SUNITINIB; ANGIOGENESIS INHIBITOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOSARCOMA; ANTIANGIOGENIC THERAPY; ARTERY INTIMAL SARCOMA; AUTOPHOSPHORYLATION; BREAST CANCER; BREAST CARCINOMA; CANCER ASSOCIATED FIBROBLAST; CANCER THERAPY; CHILDHOOD CANCER; CHRONIC MONOMYELOCYTIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DEGRADATION; DERMATOFIBROSARCOMA PROTUBERANS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; EWING SARCOMA; FIBROBLAST; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; HYPEREOSINOPHILIC SYNDROME; LARGE CELL LYMPHOMA; LEYDIG CELL TUMOR; LIVER CELL CARCINOMA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MENINGIOMA; MOLECULAR DOCKING; MONOCYTIC LEUKEMIA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; MYOFIBROBLAST; NEPHROBLASTOMA; NEUROBLASTOMA; NONHUMAN; OLIGODENDROGLIOMA; OSTEOSARCOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; UBIQUITINATION; ANIMAL; METABOLISM; NEOPLASM; NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; NEOPLASMS; PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84890467312     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/1478-811X-11-97     Document Type: Review

References (283)

1. Mechanism of action and in vivo role of platelet-derived growth factor. Heldin C-H, Westermark B, Physiol Rev 1999 79 1283 1316 (Pubitemid 29473317)
2. Role of platelet-derived growth factors in physiology and medicine. Andrae J, Gallini R, Betsholtz C, Genes Dev 2008 22 1276 1312 (Pubitemid 351717519)
3. Targeting the PDGF signaling pathway in the treatment of non-malignant diseases. Heldin C-H, J Neuroimmune Pharmacol 2013 in press
4. Tissue plasminogen activator is a potent activator of PDGF-CC. Fredriksson L, Li H, Fieber C, Li X, Eriksson U, EMBO J 2004 23 3793 3802 (Pubitemid 39389710)
5. The PDGF family: four gene products form five dimeric isoforms. Fredriksson L, Li H, Eriksson U, Cytokine Growth Factor Rev 2004 15 197 204 (Pubitemid 38781045)
6. Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Ustach CV, Kim HR, Mol Cell Biol 2005 25 6279 6288 (Pubitemid 40946575)
7. A novel signaling axis of matriptase/PDGF-D/β-PDGFR in human prostate cancer. Ustach CV, Huang W, Conley-LaComb MK, Lin CY, Che M, Abrams J, Kim HR, Cancer Res 2010 70 9631 9640
8. Immunoglobulin-like domain 4-mediated receptor-receptor interactions contribute to platelet-derived growth factor-induced receptor dimerization. Omura T, Heldin C-H, Östman A, J Biol Chem 1997 272 12676 12682 (Pubitemid 27203365)
9. Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization. Yang Y, Yuzawa S, Schlessinger J, Proc Natl Acad Sci USA 2008 105 7681 7686 (Pubitemid 351872698)
10. Full activation of the platelet-derived growth factor beta-receptor kinase involves multiple events. Baxter RM, Secrist JP, Vaillancourt RR, Kazlauskas A, J Biol Chem 1998 273 17050 17055 (Pubitemid 28311738)
11. Definition of an inhibitory juxtamembrane WW-like domain in the platelet-derived growth factor beta receptor. Irusta PM, Luo Y, Bakht O, Lai CC, Smith SO, DiMaio D, J Biol Chem 2002 277 38627 38634 (Pubitemid 35154723)
12. Autoinhibition of the platelet-derived growth factor β receptor tyrosine kinase by its C-terminal tail. Chiara F, Bishayee S, Heldin C-H, Demoulin J-B, J Biol Chem 2004 279 19732 19738 (Pubitemid 38623411)
13. Signal transduction via platelet-derived growth factor receptors. Heldin C-H, Östman A, Rönnstrand L, Biochim Biophys Acta 1998 1378 79 F113
14. Platelet-derived growth factor-induced H§ssub§2§esub§ O§ssub§2§esub§ production requires the activation of phosphatidylinositol 3-kinase. Bae YS, Sung J-Y, Kim O-S, Kim YJ, Hur KC, Kazlauskas A, Rhee SG, J Biol Chem 2000 275 10527 10531 (Pubitemid 30202116)
15. Requirement for generation of H§ssub§2§esub§O§ ssub§2§esub§ for platelet-derived growth factor signal transduction. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T, Science 1995 270 296 299
16. Negative and positive regulation of MAPK phosphatase 3 controls platelet-derived growth factor-induced Erk activation. Jurek A, Amagasaki K, Gembarska A, Heldin C-H, Lennartsson J, J Biol Chem 2009 284 4626 4634
17. Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways. Fantl WJ, Escobedo JA, Martin GA, Turck CW, del Rosario M, McCormick F, Williams LT, Cell 1992 69 413 423
18. Platelet-derived growth factor-induced signaling pathways interconnect to regulate the temporal pattern of Erk1/2 phosphorylation. Jurek A, Heldin C-H, Lennartsson J, Cell Signal 2011 23 280 287
19. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B. Haj FG, Markova B, Klaman LD, Bohmer FD, Neel BG, J Biol Chem 2003 278 739 744 (Pubitemid 36790744)
20. Site-selective regulation of platelet-derived growth factor β receptor tyrosine phosphorylation by T-cell protein tyrosine phosphatase. Persson C, Sävenhed C, Bourdeau A, Tremblay ML, Markova B, Böhmer FD, Haj FG, Neel BG, Elson A, Heldin C-H, et al. Mol Cell Biol 2004 24 2190 2201 (Pubitemid 38248956)
21. Site-selective dephosphorylation of the platelet-derived growth factor β-receptor by the receptor-like protein-tyrosine phosphatase DEP-1. Kovalenko M, Denner K, Sandström J, Persson C, Groß S, Jandt E, Vilella R, Böhmer F, Östman A, J Biol Chem 2000 275 16219 16226 (Pubitemid 30366934)
22. Dynamic changes in the expression of DEP-1 and other PDGF receptor-antagonizing PTPs during onset and termination of neointima formation. Kappert K, Paulsson J, Sparwel J, Leppänen O, Hellberg C, Östman A, Micke P, FASEB J 2007 21 523 534 (Pubitemid 46213499)
23. Regulation of the Src tyrosine kinase and Syp tyrosine phosphatase by their cellular association. Peng Z-Y, Cartwright CA, Oncogene 1995 11 1955 1962
24. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Dance M, Montagner A, Salles JP, Yart A, Raynal P, Cell Signal 2008 20 453 459
25. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Saito Y, Haendeler J, Hojo Y, Yamamoto K, Berk BC, Mol Cell Biol 2001 21 6387 6394 (Pubitemid 32927407)
26. Stimulation of β§ssub§1§esub§ integrins on fibroblasts induces PDGF independent tyrosine phosphorylation of PDGF β-receptors. Sundberg C, Rubin K, J Cell Biol 1996 132 741 752
27. Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function between LRP and the PDGF. Loukinova E, Ranganathan S, Kuznetsov S, Gorlatova N, Migliorini MM, Loukinov D, Ulery PG, Mikhailenko I, Lawrence DA, Strickland DK, J Biol Chem 2002 277 15499 15506 (Pubitemid 34967816)
28. Platelet-derived growth factor mediates tyrosine phosphorylation of the cytoplasmic domain of the low density lipoprotein receptor-related protein in caveolae. Boucher P, Liu P, Gotthardt M, Hiesberger T, Anderson RG, Herz J, J Biol Chem 2002 277 15507 15513 (Pubitemid 34967817)
29. Platelet-derived growth factor receptor-β (PDGFR-β) activation promotes its association with the low density lipoprotein receptor-related protein (LRP). Evidence for co-receptor function. Newton CS, Loukinova E, Mikhailenko I, Ranganathan S, Gao Y, Haudenschild C, Strickland DK, J Biol Chem 2005 280 27872 27878 (Pubitemid 41076904)
30. Inhibition of platelet-derived growth factor-BB-induced receptor activation and fibroblast migration by hyaluronan activation of CD44. Li L, Heldin C-H, Heldin P, J Biol Chem 2006 281 26512 26519 (Pubitemid 44401860)
31. Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation-a critical role for Cbl tyrosine kinase-binding domain. Miyake S, Mullane-Robinson KP, Lill NL, Douillard P, Band H, J Biol Chem 1999 274 16619 16628
32. Platelet-derived growth factor receptor-mediated signal transduction from endosomes. Wang Y, Pennock SD, Chen X, Kazlauskas A, Wang Z, J Biol Chem 2004 279 8038 8046 (Pubitemid 38294692)
33. Activation of protein kinase C is necessary for sorting the PDGF β-receptor to Rab4a-dependent recycling. Hellberg C, Schmees C, Karlsson S, Åhgren A, Heldin C-H, Mol Biol Cell 2009 20 2856 2863
34. Macropinocytosis of the PDGF β-receptor promotes fibroblast transformation by H-RasG12V. Schmees C, Villaseñor R, Zheng W, Ma H, Zerial M, Heldin C-H, Hellberg C, Mol Biol Cell 2012 23 2571 2582
35. The PDGF receptor is required for neural crest cell development and for normal patterning of the somites. Soriano P, Development 1997 124 2691 2700 (Pubitemid 27354815)
36. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Boström H, Willetts K, Pekny M, Levéen P, Lindahl P, Hedstrand H, Pekna M, Hellström M, Gebre-Medhin S, Schalling M, et al. Cell 1996 85 863 873 (Pubitemid 26192137)
37. Abnormal gastrointestinal development in PDGF-A and PDGFR- deficient mice implicates a novel mesenchymal structure with putative instructive properties in villus morphogenesis. Karlsson L, Lindahl P, Heath JK, Betsholtz C, Development 2000 127 3457 3466
38. Abnormal kidney development and hematological disorders in PDGF β-receptor mutant mice. Soriano P, Genes Dev 1994 8 1888 1896
39. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Levéen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C, Genes Dev 1994 8 1875 1887 (Pubitemid 24273888)
40. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Lindahl P, Johansson BR, Levéen P, Betsholtz C, Science 1997 277 242 245 (Pubitemid 27446080)
41. Alveogenesis failure in PDGF-A-deficient mice is coupled to lack of distal spreading of alveolar smooth muscle cell progenitors during lung development. Lindahl P, Karlsson L, Hellström M, Gebre-Medhin S, Willetts K, Heath JK, Betsholtz C, Development 1997 124 3943 3953 (Pubitemid 27483322)
42. A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors. Ohashi S, Natsuizaka M, Naganuma S, Kagawa S, Kimura S, Itoh H, Kalman RA, Nakagawa M, Darling DS, Basu D, et al. Cancer Res 2011 71 6836 6847
43. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Robson MC, Phillips LG, Thomason A, Robson LE, Pierce GF, Lancet 1992 339 23 25
44. A novel physiological function for platelet-derived growth factor-BB in rat dermis. Rodt SÅ Åhlén K, Berg A, Rubin K, Reed RK, J Physiol 1996 495 193 200 (Pubitemid 26288464)
45. Inhibitory DNA ligands to platelet-derived growth factor B-chain. Green LS, Jellinek D, Jenison R, Östman A, Heldin C-H, Janjic N, Biochem 1996 35 14413 14424 (Pubitemid 26384438)
46. A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. Hawthorne T, Giot L, Blake L, Kuang B, Gerwien R, Smithson G, Hahne W, Mansfield T, Starling GC, Pochart P, et al. Int J Clin Pharmacol Ther 2008 46 236 244 (Pubitemid 351663160)
47. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. Jayson GC, Parker GJ, Mullamitha S, Valle JW, Saunders M, Broughton L, Lawrance J, Carrington B, Roberts C, Issa B, et al. J Clin Oncol 2005 23 973 981 (Pubitemid 46202317)
48. An antibody directed against PDGF receptor β enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody. Shen J, Vil MD, Zhang H, Tonra JR, Rong LL, Damoci C, Prewett M, Deevi DS, Kearney J, Surguladze D, et al. Biochem Biophys Res Commun 2007 357 1142 1147 (Pubitemid 46693690)
49. Development of a fully human anti-PDGFRβ antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Shen J, Vil MD, Prewett M, Damoci C, Zhang H, Li H, Jimenez X, Deevi DS, Iacolina M, Kayas A, et al. Neoplasia 2009 11 594 604
50. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer. Socinski MA, Cancer Treat Rev 2011 37 611 617
51. Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4- yl-ethoxy) imidazo [2,1-b] [1,3] benzothiazol-2-yl] phenyl} urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. Chao Q, Sprankle KG, Grotzfeld RM, Lai AG, Carter TA, Velasco AM, Gunawardane RN, Cramer MD, Gardner MF, James J, et al. J Med Chem 2009 52 7808 7816
52. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Dohner H, Dohner K, Schittenhelm MM, Mol Cancer 2013 12 19
53. Discovery of 3-[2-(imidazo [1,2-b] \pyridazin-3-yl) ethynyl]-4-methyl-N- {4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl) phenyl} benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. Huang WS, Metcalf CA, Sundaramoorthi R, Wang Y, Zou D, Thomas RM, Zhu X, Cai L, Wen D, Liu S, et al. J Med Chem 2010 53 4701 4719
54. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. De Falco V, Buonocore P, Muthu M, Torregrossa L, Basolo F, Billaud M, Gozgit JM, Carlomagno F, Santoro M, J Clin Endocrinol Metab 2013 98 811 E819
55. PDGF receptors as cancer drug targets. Pietras K, Sjöblom T, Rubin K, Heldin C-H, Östman A, Cancer Cell 2003 3 439 443 (Pubitemid 38340290)
56. Various regions within the -helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. O'Brien KP, Seroussi E, Dal Cin P, Sciot R, Mandahl N, Fletcher JA, Turc-Carel C, Dumanski JP, Gene Chrom Cancer 1998 23 187 193 (Pubitemid 28402346)
57. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Simon M-P, Pedeutour F, Sirvent N, Grosgeorge J, Minoletti F, Coindre J-M, Terrier-Lacombe M-J, Mandahl N, Craver RD, Blin N, et al. Nature Genet 1997 15 95 98 (Pubitemid 27014958)
58. The dermatofibrosarcoma protuberans-associated collagen type I1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Shimizu A, O'Brien KP, Sjöblom T, Pietras K, Buchdunger E, Collins VP, Heldin C-H, Dumanski JP, Östman A, Cancer Res 1999 59 3719 3723 (Pubitemid 29381878)
59. PDGFRA activating mutations in gastrointestinal stromal tumors. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, et al. Science 2003 299 708 710 (Pubitemid 36159485)
60. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Toffalini F, Demoulin JB, Blood 2010 116 2429 2437
61. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU, Cancer Res 1992 52 4550 4553
62. Amplification of -platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin. Kumabe T, Sohma Y, Kayama T, Yoshimoto T, Yamamoto T, Oncogene 1992 7 627 633
63. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Puputti M, Tynninen O, Sihto H, Blom T, Maenpaa H, Isola J, Paetau A, Joensuu H, Nupponen NN, Mol Cancer Res 2006 4 927 934 (Pubitemid 46121551)
64. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. Smith JS, Wang XY, Qian J, Hosek SM, Scheithauer BW, Jenkins RB, James CD, J Neuropathol Exp Neurol 2000 59 495 503 (Pubitemid 30368309)
65. Detection of amplified oncogenes by genome DNA microarrays in human primary esophageal squamous cell carcinoma: comparison with conventional comparative genomic hybridization analysis. Arai H, Ueno T, Tangoku A, Yoshino S, Abe T, Kawauchi S, Oga A, Furuya T, Oka M, Sasaki K, Cancer Genet Cytogenet 2003 146 16 21 (Pubitemid 37117429)
66. Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors. Zhao J, Roth J, Bode-Lesniewska B, Pfaltz M, Heitz PU, Komminoth P, Genes Chromosomes Cancer 2002 34 48 57 (Pubitemid 34260596)
67. Coactivated platelet-derived growth factor receptor and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Dewaele B, Floris G, Finalet-Ferreiro J, Fletcher CD, Coindre JM, Guillou L, Hogendoorn PC, Wozniak A, Vanspauwen V, Schoffski P, et al. Cancer Res 2010 70 7304 7314
68. A human brain tumor-derived PDGFR- deletion mutant is transforming. Clarke ID, Dirks PB, Oncogene 2003 22 722 733 (Pubitemid 36269285)
69. Epithelial-mesenchymal transitions in development and disease. Thiery JP, Acloque H, Huang RY, Nieto MA, Cell 2009 139 871 890
70. Autocrine PDGFR signaling promotes mammary cancer metastasis. Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, Donovan M, Cordon-Cardo C, Beug H, Grunert S, J Clin Invest 2006 116 1561 1570
71. High interstitial fluid pressure-an obstacle in cancer therapy. Heldin C-H, Rubin K, Pietras K, Östman A, Nat Rev Cancer 2004 4 806 813 (Pubitemid 39331152)
72. Oncogene addiction. Weinstein IB, Joe A, Cancer Res 2008 68 3077 3080
73. The biology of primate retrovirus. Deinhardt F, Viral oncology New York: Raven Press, Klein G, 1980 359 398
74. Platelet-derived growth factor is structurally related to the putative transforming protein p28§ssup§sis§esup§ of simian sarcoma virus. Waterfield MD, Scrace GT, Whittle N, Stroobant P, Johnsson A, Wasteson Å Westermark B, Heldin C-H, Huang JS, Deuel TF, Nature (London) 1983 304 35 39 (Pubitemid 13063102)
75. Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor. Doolittle RF, Hunkapiller MW, Hood LE, Devare SD, Robbins KC, Aaronson SA, Antoniades HN, Science 1983 221 275 277 (Pubitemid 13062620)
76. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor- and their receptors in human malignant glioma cell lines. Nistér M, Libermann TA, Betsholtz C, Pettersson M, Claesson-Welsh L, Heldin C-H, Schlessinger J, Westermark B, Cancer Res 1988 48 3910 3918
77. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA, Cancer Res 2002 62 3729 3735 (Pubitemid 34728854)
78. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin C-H, Westermark B, Nistér M, Cancer Res 1992 52 3213 3219
79. Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Di Rocco F, Carroll RS, Zhang JP, Black PM, Neurosurgery 1998 42 341 346 (Pubitemid 28076794)
80. Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Martinho O, Longatto-Filho A, Lambros MB, Martins A, Pinheiro C, Silva A, Pardal F, Amorim J, Mackay A, Milanezi F, et al. Br J Cancer 2009 101 973 982
81. Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor receptor expression in human malignant gliomas. Hermanson M, Funa K, Koopmann J, Maintz D, Waha A, Westermark B, Heldin C-H, Wiestler OD, Louis DN, von Deimling A, Nistér M, Cancer Res 1996 56 164 171 (Pubitemid 26010396)
82. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Guha A, Dashner K, Black PM, Wagner JA, Stiles CD, Int J Cancer 1995 60 168 173
83. Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. Maxwell M, Naber SP, Wolfe HJ, Galanopoulos T, Hedley-Whyte ET, Black PM, Antoniades HN, J Clin Invest 1990 86 131 140 (Pubitemid 20226985)
84. Platelet-derived growth factor receptor-β is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Plate KH, Breier G, Farrell CL, Risau W, Lab Invest 1992 67 529 534
85. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Rand V, Huang J, Stockwell T, Ferriera S, Buzko O, Levy S, Busam D, Li K, Edwards JB, Eberhart C, et al. Proc Natl Acad Sci U S A 2005 102 14344 14349 (Pubitemid 41429700)
86. Overexpression and amplification of alpha-PDGF receptor gene lacking exons coding for a portion of the extracellular region in a malignant glioma. Kumabe T, Sohma Y, Kayama T, Yoshimoto T, Yamamoto T, Tohoku J Exp Med 1992 168 265 269
87. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. Cancer Cell 2010 17 98 110
88. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. Paugh BS, Zhu X, Qu C, Endersby R, Diaz AK, Zhang J, Bax DA, Carvalho D, Reis RM, Onar-Thomas A, et al. Cancer Res 2013 73 6219 6229
89. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Ozawa T, Brennan CW, Wang L, Squatrito M, Sasayama T, Nakada M, Huse JT, Pedraza A, Utsuki S, Yasui Y, et al. Genes Dev 2010 24 2205 2218
90. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Uhrbom L, Hesselager G, Nistér M, Westermark B, Cancer Res 1998 58 5275 5279 (Pubitemid 28551098)
91. Dependence of autocrine growth factor stimulation in platelet-derived growth factor-B-induced mouse brain tumor cells. Uhrbom L, Hesselager G, Östman A, Nistér M, Westermark B, Int J Cancer 2000 85 398 406 (Pubitemid 30030415)
92. Complementary effects of platelet-derived growth factor autocrine stimulation and p53 or Ink4a-Arf deletion in a mouse glioma model. Hesselager G, Uhrbom L, Westermark B, Nister M, Cancer Res 2003 63 4305 4309 (Pubitemid 36950994)
93. Defective DNA double-strand break repair underlies enhanced tumorigenesis and chromosomal instability in p27-deficient mice with growth factor-induced oligodendrogliomas. See WL, Miller JP, Squatrito M, Holland E, Resh MD, Koff A, Oncogene 2010 29 1720 1731
94. Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma. Tchougounova E, Kastemar M, Brasater D, Holland EC, Westermark B, Uhrbom L, Oncogene 2007 26 6289 6296 (Pubitemid 47462106)
95. SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans. Liu KW, Feng H, Bachoo R, Kazlauskas A, Smith EM, Symes K, Hamilton RL, Nagane M, Nishikawa R, Hu B, Cheng SY, J Clin Invest 2011 121 905 917
96. PDGF-B induces a homogeneous class of oligodendrogliomas from embryonic neural progenitors. Appolloni I, Calzolari F, Tutucci E, Caviglia S, Terrile M, Corte G, Malatesta P, Int J Cancer 2009 124 2251 2259
97. Tumor progression and oncogene addiction in a PDGF-B-induced model of gliomagenesis. Calzolari F, Appolloni I, Tutucci E, Caviglia S, Terrile M, Corte G, Malatesta P, Neoplasia 2008 10 1373 1382 following 1382
98. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC, Genes Dev 2001 15 1913 1925 (Pubitemid 32738621)
99. Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. Assanah M, Lochhead R, Ogden A, Bruce J, Goldman J, Canoll P, J Neurosci 2006 26 6781 6790 (Pubitemid 44315239)
100. Brain abnormalities and glioma-like lesions in mice overexpressing the long isoform of PDGF-A in astrocytic cells. Nazarenko I, Hedren A, Sjodin H, Orrego A, Andrae J, Afink GB, Nister M, Lindstrom MS, PLoS One 2011 6 18303
101. Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Kim Y, Kim E, Wu Q, Guryanova O, Hitomi M, Lathia JD, Serwanski D, Sloan AE, Weil RJ, Lee J, et al. Genes Dev 2012 26 1247 1262
102. PDGF-B can sustain self-renewal and tumorigenicity of experimental glioma-derived cancer-initiating cells by preventing oligodendrocyte differentiation. Jiang Y, Boije M, Westermark B, Uhrbom L, Neoplasia 2011 13 492 503
103. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, Van Etten RA, et al. Blood Cells Mol Dis 2005 34 181 185 (Pubitemid 40250495)
104. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American brain tumor consortium study 99-08. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, et al. Clin Cancer Res 2006 12 4899 4907 (Pubitemid 44338577)
105. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European organisation for research and treatment of cancer brain tumor group study. Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, et al. J Clin Oncol 2008 26 4659 4665
106. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, Blomquist E, Gordower L, Schultz H, Raizer J, et al. Br J Cancer 2009 101 1995 2004
107. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Dresemann G, Ann Oncol 2005 16 1702 1708 (Pubitemid 41510147)
108. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Dresemann G, Weller M, Rosenthal MA, Wedding U, Wagner W, Engel E, Heinrich B, Mayer-Steinacker R, Karup-Hansen A, Fluge O, et al. J Neurooncol 2010 96 393 402
109. Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma. Moreno L, Popov S, Jury A, Al Sarraj S, Jones C, Zacharoulis S, J Neurooncol 2013 111 169 176
110. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, Stacchiotti S, Pastore E, Gronchi A, Perrone F, et al. Clin Cancer Res 2006 12 6920 6928 (Pubitemid 44974484)
111. Phase II study of imatinib in advanced chordoma. Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, Bertuzzi A, Tamborini E, Pilotti S, Messina A, et al. J Clin Oncol 2012 30 914 920
112. Phase II study of imatinib mesylate for recurrent meningiomas (North American brain tumor consortium study 01-08). Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, et al. Neuro Oncol 2009 11 853 860
113. Phase II study of Gleevec (R) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE 2nd, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, et al. J Neurooncol 2012 106 409 415
114. Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis. Horak P, Wohrer A, Hassler M, Hainfellner J, Preusser M, Marosi C, J Neurooncol 2012 109 323 330
115. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate). Mukherjee J, Kamnasaran D, Balasubramaniam A, Radovanovic I, Zadeh G, Kiehl TR, Guha A, Cancer Res 2009 69 5099 5107
116. Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells. Sabha N, Au K, Agnihotri S, Singh S, Mangat R, Guha A, Zadeh G, PLoS One 2012 7 39412
117. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Ammoun S, Schmid MC, Triner J, Manley P, Hanemann CO, Neuro Oncol 2011 13 759 766
118. Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results. Malhotra B, Schuetze SM, Curr Opin Oncol 2012 24 419 424
119. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Patel KU, Szabo SS, Hernandez VS, Prieto VG, Abruzzo LV, Lazar AJ, Lopez-Terrada D, Hum Pathol 2008 39 184 193
120. Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Greco A, Roccato E, Miranda C, Cleris L, Formelli F, Pierotti MA, Int J Cancer 2001 92 354 360 (Pubitemid 32249711)
121. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Sjöblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Östman A, Heldin C-H, Cancer Res 2001 61 5778 5783 (Pubitemid 32769094)
122. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, Bruckner JD, J Clin Oncol 2002 20 3586 3591 (Pubitemid 34983217)
123. Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans. Price VE, Fletcher JA, Zielenska M, Cole W, Viero S, Manson DE, Stuart M, Pappo AS, Pediatr Blood Cancer 2005 44 511 515 (Pubitemid 40614501)
124. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR, Int J Cancer 2002 100 623 626 (Pubitemid 34832970)
125. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Labropoulos SV, Fletcher JA, Oliveira AM, Papadopoulos S, Razis ED, Anti-cancer drugs 2005 16 461 466 (Pubitemid 40434613)
126. Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. Mizutani K, Tamada Y, Hara K, Tsuzuki T, Saeki H, Tamaki K, Matsumoto Y, Br J Dermatol 2004 151 235 237 (Pubitemid 39061309)
127. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225. McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA, J Clin Oncol 2005 23 866 873 (Pubitemid 46224187)
128. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, et al. Clin Cancer Res 2008 14 2717 2725
129. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, et al. J Clin Oncol 2010 28 1772 1779
130. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. Stacchiotti S, Pedeutour F, Negri T, Conca E, Marrari A, Palassini E, Collini P, Keslair F, Morosi C, Gronchi A, et al. Int J Cancer 2011 129 1761 1772
131. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Kerob D, Porcher R, Verola O, Dalle S, Maubec E, Aubin F, D'Incan M, Bodokh I, Boulinguez S, Madelaine-Chambrin I, et al. Clin Cancer Res 2010 16 3288 3295
132. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, et al. J Clin Oncol 2003 21 4342 4349 (Pubitemid 46621810)
133. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al. The New England journal of medicine 2002 347 472 480 (Pubitemid 34879334)
134. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, et al. Lancet 2004 364 1127 1134 (Pubitemid 39296599)
135. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, et al. Lancet 2006 368 1329 1338 (Pubitemid 44528723)
136. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, et al. Clin Cancer Res 2009 15 5910 5916
137. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Montemurro M, Schoffski P, Reichardt P, Gelderblom H, Schutte J, Hartmann JT, von Moos R, Seddon B, Joensuu H, Wendtner CM, et al. Eur J Cancer 2009 45 2293 2297
138. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, et al. N Engl J Med 2010 362 2251 2259
139. Coexpression of a PDGF-like growth factor and PDGF receptors in a human osteosarcoma cell line: Implications for autocrine receptor activation. Betsholtz C, Westermark B, Ek B, Heldin C-H, Cell 1984 39 447 457 (Pubitemid 15198584)
140. Expression of platelet-derived growth factor and its receptors in proliferative disorders of fibroblastic origin. Smits A, Funa K, Vassbotn FS, Beausang-Linder M, af Ekenstam F, Heldin C-H, Westermark B, Nistér M, Am J Pathol 1992 140 639 648
141. Cell proliferation in human soft tissue tumors correlates with platelet-derived growth factor B chain expression: an immunohistochemical and in situ hybridization study. Wang J, Coltrera MD, Gown AM, Cancer Res 1994 54 560 564
142. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Kubo T, Piperdi S, Rosenblum J, Antonescu CR, Chen W, Kim HS, Huvos AG, Sowers R, Meyers PA, Healey JH, Gorlick R, Cancer 2008 112 2119 2129 (Pubitemid 351628620)
143. PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Ho AL, Vasudeva SD, Lae M, Saito T, Barbashina V, Antonescu CR, Ladanyi M, Schwartz GK, Cancer Res 2012 72 4515 4525
144. Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines. Zwerner JP, May WA, Oncogene 2002 21 3847 3854 (Pubitemid 34620852)
145. Distinct effects of ligand-induced PDGFR and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments. Ehnman M, Missiaglia E, Folestad E, Selfe J, Strell C, Thway K, Brodin B, Pietras K, Shipley J, Ostman A, Eriksson U, Cancer Res 2013 73 2139 2149
146. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Taniguchi E, Nishijo K, McCleish AT, Michalek JE, Grayson MH, Infante AJ, Abboud HE, Legallo RD, Qualman SJ, Rubin BP, Keller C, Oncogene 2008 27 6550 6560
147. Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: a report from the children's oncology group. Blandford MC, Barr FG, Lynch JC, Randall RL, Qualman SJ, Keller C, Pediatr Blood Cancer 2006 46 329 338 (Pubitemid 43201849)
148. Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients. Armistead PM, Salganick J, Roh JS, Steinert DM, Patel S, Munsell M, El-Naggar AK, Benjamin RS, Zhang W, Trent JC, Cancer 2007 110 2293 2303 (Pubitemid 350100752)
149. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schoffski P, Aglietta M, Staddon AP, Beppu Y, et al. Lancet 2012 379 1879 1886
150. Expression of platelet-derived growth factor and its receptors in spontaneous canine hemangiosarcoma and cutaneous hemangioma. Asa SA, Murai A, Murakami M, Hoshino Y, Mori T, Maruo K, Khater A, El-Sawak A, El-Aziz EA, Yanai T, Sakai H, Histol Histopathol 2012 27 601 607
151. Imatinib and dasatinib inhibit hemangiosarcoma and implicate PDGFR-β and Src in tumor growth. Dickerson EB, Marley K, Edris W, Tyner JW, Schalk V, Macdonald V, Loriaux M, Druker BJ, Helfand SC, Transl Oncol 2013 6 158 168
152. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t (5;12) chromosomal translocation. Golub TR, Barker GF, Lovett M, Gilliland DG, Cell 1994 77 307 316 (Pubitemid 24138627)
153. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor β receptor in chronic myelomonocytic leukemia. Magnusson MK, Meade KE, Brown KE, Arthur DC, Krueger LA, Barrett AJ, Dunbar CE, Blood 2001 98 2518 2525
154. Transforming properties of the Huntingtin interacting protein 1/platelet-derived growth factor beta receptor fusion protein. Ross TS, Gilliland DG, J Biol Chem 1999 274 22328 22336
155. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor β gene in atypical chronic myeloid leukemia with t (5;10) (q33; q22). Schwaller J, Anastasiadou E, Cain D, Kutok J, Wojiski S, Williams IR, LaStarza R, Crescenzi B, Sternberg DW, Andreasson P, et al. Blood 2001 97 3910 3918
156. KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia. Medves S, Duhoux FP, Ferrant A, Toffalini F, Ameye G, Libouton JM, Poirel HA, Demoulin JB, Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2010 24 1052 1055
157. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, et al. N Engl J Med 2003 348 1201 1214 (Pubitemid 36359296)
158. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R, Proc Natl Acad Sci USA 2003 100 7830 7835 (Pubitemid 36760055)
159. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, et al. Blood 2003 102 3093 3096 (Pubitemid 37314742)
160. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Elling C, Erben P, Walz C, Frickenhaus M, Schemionek M, Stehling M, Serve H, Cross NC, Hochhaus A, Hofmann WK, et al. Blood 2011 117 2935 2943
161. Critical role of the platelet-derived growth factor receptor (PDGFR) β transmembrane domain in the TEL-PDGFRβ cytosolic oncoprotein. Toffalini F, Hellberg C, Demoulin J-B, J Biol Chem 2010 285 12268 12278
162. Activation of FIP1L1-PDGFR requires disruption of the juxtamembrane domain of PDGFR and is FIP1L1-independent. Stover EH, Chen J, Folens C, Lee BH, Mentens N, Marynen P, Williams IR, Gilliland DG, Cools J, Proc Natl Acad Sci USA 2006 103 8078 8083 (Pubitemid 43801055)
163. The fusion proteins TEL-PDGFRβ and FIP1L1-PDGFR escape ubiquitination and degradation. Toffalini F, Kallin A, Vandenberghe P, Pierre P, Michaux L, Cools J, Demoulin JB, Haematologica 2009 94 1085 1093
164. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR-induced myeloproliferative disease. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, Curley DP, Duclos N, Rowan R, Kutok JL, et al. Cancer Cell 2003 3 459 469 (Pubitemid 38340293)
165. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, Metcalfe DD, Nutman TB, Blood 2003 101 4660 4666 (Pubitemid 36857718)
166. FIP1L1-PDGFR imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells. Fukushima K, Matsumura I, Ezoe S, Tokunaga M, Yasumi M, Satoh Y, Shibayama H, Tanaka H, Iwama A, Kanakura Y, J Biol Chem 2009 284 7719 7732
167. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Buitenhuis M, Verhagen LP, Cools J, Coffer PJ, Cancer Res 2007 67 3759 3766 (Pubitemid 46762162)
168. ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB. Montano-Almendras CP, Essaghir A, Schoemans H, Varis I, Noel LA, Velghe AI, Latinne D, Knoops L, Demoulin JB, Haematologica 2012 97 1064 1072
169. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, et al. N Engl J Med 2002 347 481 487 (Pubitemid 34879335)
170. Treatment of hypereosinophilic syndrome with imatinib mesilate. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH, Lancet 2002 359 1577 1578 (Pubitemid 34621126)
171. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, Rios MB, Letvak L, Kaled ES, Kantarjian H, Blood 2003 101 4714 4716 (Pubitemid 36857726)
172. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H, Leuk Res 2002 26 881 884 (Pubitemid 34790218)
173. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ, Witzig TE, Cross NC, Tefferi A, Blood 2003 101 3391 3397 (Pubitemid 36857919)
174. Stable expression of small interfering RNA sensitizes TEL-PDGFβR to inhibition with imatinib or rapamycin. Chen J, Wall NR, Kocher K, Duclos N, Fabbro D, Neuberg D, Griffin JD, Shi Y, Gilliland DG, J Clin Invest 2004 113 1784 1791 (Pubitemid 39071670)
175. Sorafenib is a potent inhibitor of FIP1L1-PDGFR and the imatinib-resistant FIP1L1-PDGFR T674I mutant. Lierman E, Folens C, Stover EH, Mentens N, Van Miegroet H, Scheers W, Boogaerts M, Vandenberghe P, Marynen P, Cools J, Blood 2006 108 1374 1376 (Pubitemid 44232039)
176. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFR in vitro and in vivo. Stover EH, Chen J, Lee BH, Cools J, McDowell E, Adelsperger J, Cullen D, Coburn A, Moore SA, Okabe R, et al. Blood 2005 106 3206 3213 (Pubitemid 41565920)
177. The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro. von Bubnoff N, Gorantla SP, Engh RA, Oliveira TM, Thone S, Aberg E, Peschel C, Duyster J, Oncogene 2011 30 933 943
178. Platelet-derived growth factor is a potent biologic response modifier of T cells. Daynes RA, Dowell T, Araneo BA, J Exp Med 1991 174 1323 1333
179. Inhibition of human natural killer cell activity by platelet-derived growth factor (PDGF): III membrane binding studies and differential biological effect of recombinant PDGF isoforms. Gersuk GM, Westermark B, Mohabeer AJ, Challita PM, Pattamakom S, Pattengale PK, Scand J Immunol 1991 33 521 532
180. Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Yang J, Liu X, Nyland SB, Zhang R, Ryland LK, Broeg K, Baab KT, Jarbadan NR, Irby R, Loughran TP Jr, Blood 2010 115 51 60
181. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, et al. Nat Med 2012 18 1699 1704
182. A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, DePaoli A, Hannah A, Balk SP, Bubley GJ, Clin Cancer Res 2001 7 800 805 (Pubitemid 32708713)
183. Gene expression correlates of clinical prostate cancer behavior. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, et al. Cancer Cell 2002 1 203 209 (Pubitemid 41039166)
184. A potential oncogenic activity of platelet-derived growth factor D in prostate cancer progression. Ustach CV, Taube ME, Hurst NJ Jr, Bhagat S, Bonfil RD, Cher ML, Schuger L, Kim HR, Cancer Res 2004 64 1722 1729 (Pubitemid 38428694)
185. PTEN regulates PDGF ligand switch for beta-PDGFR signaling in prostate cancer. Conley-LaComb MK, Huang W, Wang S, Shi D, Jung YS, Najy A, Fridman R, Bonfil RD, Cher ML, Chen YQ, Kim HR, Am J Pathol 2012 180 1017 1027
186. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S, Sarkar FH, PLoS One 2010 5 12445
187. Differential tumorigenic potential and matriptase activation between PDGF B versus PDGF D in prostate cancer. Najy AJ, Won JJ, Movilla LS, Kim HR, Mol Cancer Res 2012 10 1087 1097
188. A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth. Huang W, Fridman Y, Bonfil RD, Ustach CV, Conley-LaComb MK, Wiesner C, Saliganan A, Cher ML, Kim HR, Oncogene 2012 31 4527 4535
189. Human bone marrow activates the Akt pathway in metastatic prostate cells through transactivation of the alpha-platelet-derived growth factor receptor. Dolloff NG, Russell MR, Loizos N, Fatatis A, Cancer Res 2007 67 555 562 (Pubitemid 46192192)
190. The receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Russell MR, Jamieson WL, Dolloff NG, Fatatis A, Oncogene 2009 28 412 421
191. Inhibition of prostate cancer using RNA interference-directed knockdown of platelet-derived growth factor receptor. Park YH, Seo SY, Ha M, Ku JH, Kim HH, Kwak C, Urology 2011 77 1509 e1509-1515
192. The receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms. Russell MR, Liu Q, Lei H, Kazlauskas A, Fatatis A, Cancer Res 2010 70 4195 4203
193. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P, Fidler IJ, J Natl Cancer Inst 2003 95 458 470 (Pubitemid 36432420)
194. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Kim SJ, Uehara H, Yazici S, Langley RR, He J, Tsan R, Fan D, Killion JJ, Fidler IJ, Cancer Res 2004 64 4201 4208 (Pubitemid 38802424)
195. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim SJ, Fidler IJ, Logothetis C, J Clin Oncol 2004 22 3323 3329 (Pubitemid 41103689)
196. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, et al. Clin Cancer Res 2007 13 5816 5824 (Pubitemid 47583906)
197. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. Mathew P, Thall PF, Wen S, Bucana C, Jones D, Horne E, Oh WK, Morris MJ, Lee YC, Logothetis CJ, et al. Br J Cancer 2008 99 1426 1432
198. Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction. Najy AJ, Jung YS, Won JJ, Conley-LaComb MK, Saliganan A, Kim CJ, Heath E, Cher ML, Bonfil RD, Kim HR, Prostate 2012 72 1328 1338
199. A crucial function of PDGF in TGF-β-mediated cancer progression of hepatocytes. Gotzmann J, Fischer AN, Zojer M, Mikula M, Proell V, Huber H, Jechlinger M, Waerner T, Weith A, Beug H, Mikulits W, Oncogene 2006 25 3170 3185 (Pubitemid 43881558)
200. PDGF essentially links TGF-β signaling to nuclear β-catenin accumulation in hepatocellular carcinoma progression. Fischer AN, Fuchs E, Mikula M, Huber H, Beug H, Mikulits W, Oncogene 2007 26 3395 3405 (Pubitemid 46788880)
201. Sorafenib in advanced hepatocellular carcinoma. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. N Engl J Med 2008 359 378 390
202. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al. Lancet Oncol 2009 10 25 34
203. Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma. Boonjaraspinyo S, Boonmars T, Wu Z, Loilome W, Sithithaworn P, Nagano I, Pinlaor S, Yongvanit P, Nielsen PS, Pairojkul C, Khuntikeo N, Tumour Biol 2012 33 1785 1802
204. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells. Sugiyama H, Onuki K, Ishige K, Baba N, Ueda T, Matsuda S, Takeuchi K, Onodera M, Nakanuma Y, Yamato M, et al. J Gastroenterol 2011 46 779 789
205. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Fingas CD, Bronk SF, Werneburg NW, Mott JL, Guicciardi ME, Cazanave SC, Mertens JC, Sirica AE, Gores GJ, Hepatology 2011 54 2076 2088
206. Targeting PDGFR-β in cholangiocarcinoma. Fingas CD, Mertens JC, Razumilava N, Bronk SF, Sirica AE, Gores GJ, Liver Int 2012 32 400 409
207. Expression in lung carcinomas of platelet-derived growth factor and its receptors. Kawai T, Hiroi S, Torikata C, Lab Invest 1997 77 431 436 (Pubitemid 27508614)
208. Expression of functionally intact PDGF receptors in highly metastatic 3LL Lewis lung carcinoma cells. Fitzer-Attas C, Feldman M, Eisenbach L, Int J Cancer 1993 53 315 322 (Pubitemid 23042885)
209. Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth factor (PDGF) and PDGF receptor mRNAs and their protein products. Antoniades HN, Galanopoulos T, Neville-Golden J, O'Hara CJ, Proc Natl Acad Sci USA 1992 89 3942 3946
210. Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-β) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer. Tsao AS, Wei W, Kuhn E, Spencer L, Solis LM, Suraokar M, Lee JJ, Hong WK, Wistuba II, Clin Lung Cancer 2011 12 369 374
211. Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Busund LT, Bremnes RM, J Thorac Oncol 2008 3 963 970
212. Inhibition of platelet-derived growth factor receptor by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer. Laing N, McDermott B, Wen S, Yang D, Lawson D, Collins M, Reimer C, Hall PA, Andersen H, Snaith M, et al. Mol Pharmacol 2013 83 1247 1256
213. Combined anti-PDGFR and PDGFRβ targeting in non-small cell lung cancer. Reinmuth N, Liersch R, Raedel M, Fehrmann F, Fehrmann N, Bayer M, Schwoeppe C, Kessler T, Berdel W, Thomas M, Mesters RM, Int J Cancer 2009 124 1535 1544
214. Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer. Huang CH, Williamson SK, Van Veldhuizen PJ, Hsueh CT, Allen A, Tawfik O, Wick J, Smith H, Uypeckcuat AM, Mayo M, Kelly K, J Thorac Oncol 2011 6 372 377
215. Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population. Ping G, Hui-Min W, Wei-Min W, Bao-Hui H, Med Oncol 2011 28 578 583
216. Localization of platelet-derived growth factor β receptor expression in the periepithelial stroma of human breast carcinoma. Bhardwaj B, Klassen J, Cossette N, Sterns E, Tuck A, Deeley R, Sengupta S, Elliott B, Clin Cancer Res 1996 2 773 782 (Pubitemid 26135343)
217. Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor β subunit in human breast tissue and breast carcinoma. Coltrera MD, Wang J, Porter PL, Gown AM, Cancer Res 1995 55 2703 2708
218. Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer. Seymour L, Bezwoda WR, Breast Cancer Res Treat 1994 32 229 233 (Pubitemid 24313348)
219. Overexpression of platelet-derived growth factor receptor in breast cancer is associated with tumour progression. Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F, Breast Cancer Res 2005 7 788 R795
220. Mammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptors. Campbell CI, Moorehead RA, BMC cancer 2011 11 480
221. In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells. Weigel MT, Dahmke L, Schem C, Bauerschlag DO, Weber K, Niehoff P, Bauer M, Strauss A, Jonat W, Maass N, Mundhenke C, BMC cancer 2010 10 412
222. Epithelial-mesenchymal transition in breast cancer lines is mediated through PDGF-D released by tissue-resident stem cells. Devarajan E, Song YH, Krishnappa S, Alt E, Int J Cancer 2012 131 1023 1031
223. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Weigel MT, Ghazoui Z, Dunbier A, Pancholi S, Dowsett M, Martin LA, Breast Cancer Res 2012 14 78
224. Stromal expression of platelet-derived growth factor β-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lindmark G, Sundberg C, Glimelius B, Påhlman L, Rubin K, Gerdin B, Lab Invest 1993 69 682 689 (Pubitemid 24026849)
225. Microvascular pericytes express platelet-derived growth factor-β receptors in human healing wounds and colorectal adenocarcinoma. Sundberg C, Ljungström M, Lindmark G, Gerdin B, Rubin K, Am J Pathol 1993 143 1377 1388 (Pubitemid 24057108)
226. The death receptor CD95 activates the cofilin pathway to stimulate tumour cell invasion. Steller EJ, Ritsma L, Raats DA, Hoogwater FJ, Emmink BL, Govaert KM, Laoukili J, Rinkes IH, van Rheenen J, Kranenburg O, EMBO Rep 2011 12 931 937
227. PDGFR/β expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy. Wehler TC, Frerichs K, Graf C, Drescher D, Schimanski K, Biesterfeld S, Berger MR, Kanzler S, Junginger T, Galle PR, et al. Oncol Rep 2008 19 697 704 (Pubitemid 351330438)
228. Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Hamilton SR, Fidler IJ, Int J Cancer 2006 119 2567 2574 (Pubitemid 44691309)
229. PDGFRB promotes liver metastasis formation of mesenchymal-like colorectal tumor cells. Steller EJ, Raats DA, Koster J, Rutten B, Govaert KM, Emmink BL, Snoeren N, van Hooff SR, Holstege FC, Maas C, et al. Neoplasia 2013 15 204 217
230. Mesothelioma cell proliferation through autocrine activation of PDGF-ββ receptor. Honda M, Kanno T, Fujita Y, Gotoh A, Nakano T, Nishizaki T, Cell Physiol Biochem 2012 29 667 674
231. Expression and prognostic value of platelet-derived growth factor-AA and its receptor in nephroblastoma. Ghanem M, Nijman R, Safan M, van der Kwast T, Vansteenbrugge G, BJU Int 2010 106 1389 1393
232. Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Seymour L, Dajee D, Bezwoda WR, Breast Cancer Res Treat 1993 26 247 252 (Pubitemid 23304240)
233. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Henriksen R, Funa K, Wilander E, Bäckström T, Ridderheim M, Öberg K, Cancer Res 1993 53 4550 4554 (Pubitemid 23304378)
234. Usefulness of platelet-derived growth factor as a prognostic factor in pulmonary adenocarcinoma. Takanami I, Imamura T, Yamamoto Y, Kodaira S, J Surg Oncol 1995 58 40 43
235. Human neuroblastoma cells express and β platelet-derived growth factor receptors coupling with neurotrophic and chemotactic signaling. Matsui T, Sano K, Tsukamoto T, Ito M, Takaishi T, Nakata H, Nakamura H, Chihara K, J Clin Invest 1993 92 1153 1160 (Pubitemid 23273886)
236. Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors. Uccini S, Mannarino O, McDowell HP, Pauser U, Vitali R, Natali PG, Altavista P, Andreano T, Coco S, Boldrini R, et al. Clin Cancer Res 2005 11 380 389 (Pubitemid 40075818)
237. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a children's oncology group study. Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, Adamson PC, Pediatr Blood Cancer 2008 50 254 258
238. A role of PDGFR in basal cell carcinoma proliferation. Xie J, Aszterbaum M, Zhang X, Bonifas JM, Zachary C, Epstein E, McCormick F, Proc Natl Acad Sci U S A 2001 98 9255 9259 (Pubitemid 32743903)
239. Platelet-derived growth factor receptor β-subtype regulates proliferation and migration of gonocytes. Basciani S, De Luca G, Dolci S, Brama M, Arizzi M, Mariani S, Rosano G, Spera G, Gnessi L, Endocrinology 2008 149 6226 6235
240. Lack of efficacy of imatinib in a patient with metastatic leydig cell tumor. Froehner M, Beuthien-Baumann B, Dittert DD, Schuler U, Wirth MP, Cancer Chemother Pharmacol 2006 58 716 718 (Pubitemid 44167399)
241. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germa JR, Capella G, Villanueva A, Vinals F, Clin Cancer Res 2009 15 3384 3395
242. Significantly high expression of platelet-derived growth factor (PDGF) in benign nodules of the thyroid: relevance in the development of goitre recurrence? Malkomes P, Oppermann E, Bechstein WO, Holzer K, Langenbecks Arch Surg 2011 396 1165 1172
243. Tumor angiogenesis. Kerbel RS, N Engl J Med 2008 358 2039 2049 (Pubitemid 351656458)
244. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Sennino B, Falcon BL, McCauley D, Le T, McCauley T, Kurz JC, Haskell A, Epstein DM, McDonald DM, Cancer Res 2007 67 7358 7367 (Pubitemid 47206566)
245. Soluble receptor-mediated selective inhibition of VEGFR and PDGFRβ signaling during physiologic and tumor angiogenesis. Kuhnert F, Tam BY, Sennino B, Gray JT, Yuan J, Jocson A, Nayak NR, Mulligan RC, McDonald DM, Kuo CJ, Proc Natl Acad Sci USA 2008 105 10185 10190
246. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P, Faseb J 2004 18 338 340
247. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Hasumi Y, Klosowska-Wardega A, Furuhashi M, Östman A, Heldin C-H, Hellberg C, Int J Cancer 2007 121 2606 2614 (Pubitemid 350136402)
248. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D, J Clin Invest 2003 111 1287 1295 (Pubitemid 36554699)
249. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, Geissler EK, Stoeltzing O, Lang SA, Mol Cancer Ther 2011 10 2157 2167
250. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Kaminker J, Ferrara N, Cancer Cell 2009 15 21 34
251. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. McCarty MF, Somcio RJ, Stoeltzing O, Wey J, Fan F, Liu W, Bucana C, Ellis LM, J Clin Invest 2007 117 2114 2122 (Pubitemid 47219556)
252. Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Ho IA, Toh HC, Ng WH, Teo YL, Guo CM, Hui KM, Lam PY, Stem Cells 2013 31 146 155
253. PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Xue Y, Lim S, Yang Y, Wang Z, Jensen LD, Hedlund EM, Andersson P, Sasahara M, Larsson O, Galter D, et al. Nat Med 2012 18 100 110
254. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic
255. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cao R, Björndahl MA, Religa P, Clasper S, Garvin S, Galter D, Meister B, Ikomi F, Tritsaris K, Dissing S, et al. Cancer Cell 2004 6 333 345 (Pubitemid 39361435)
256. Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor β is associated with lymphatic metastasis in human gastric carcinoma. Kodama M, Kitadai Y, Sumida T, Ohnishi M, Ohara E, Tanaka M, Shinagawa K, Tanaka S, Yasui W, Chayama K, Cancer Sci 2010 101 1984 1989
257. Platelet-derived growth factor receptor promotes lymphatic metastases in papillary thyroid cancer. Zhang J, Wang P, Dykstra M, Gelebart P, Williams D, Ingham R, Adewuyi EE, Lai R, McMullen T, J Pathol 2012 228 241 250
258. Hallmarks of cancer: interactions with the tumor stroma. Pietras K, Östman A, Exp Cell Res 2010 316 1324 1331
259. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Hanahan D, Coussens LM, Cancer Cell 2012 21 309 322
260. Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Forsberg K, Valyi-Nagy I, Heldin C-H, Herlyn M, Westermark B, Proc Natl Acad Sci U S A 1993 90 393 397 (Pubitemid 23028868)
261. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Skobe M, Fusenig NE, Proc Natl Acad Sci U S A 1998 95 1050 1055 (Pubitemid 28124910)
262. Platelet-derived growth factor-BB accelerates prostate cancer growth by promoting the proliferation of mesenchymal stem cells. Cheng J, Ye H, Liu Z, Xu C, Zhang Z, Liu Y, Sun Y, J Cell Biochem 2013 114 1510 1518
263. Human breast carcinoma desmoplasia is PDGF initiated. Shao Z-M, Nguyen M, Barsky SH, Oncogene 2000 19 4337 4345
264. Tumor-driven paracrine platelet-derived growth factor receptor signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. Tejada ML, Yu L, Dong J, Jung K, Meng G, Peale FV, Frantz GD, Hall L, Liang X, Gerber HP, Ferrara N, Clin Cancer Res 2006 12 2676 2688
265. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, Haran AC, Odell MM, Bauer RL, Ren HP, Haugen HS, et al. Proc Natl Acad Sci U S A 2005 102 3389 3394 (Pubitemid 40328055)
266. Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Anderberg C, Li H, Fredriksson L, Andrae J, Betsholtz C, Li X, Eriksson U, Pietras K, Cancer Res 2009 69 369 378
267. Paracrine signalling in colorectal liver metastases involving tumor cell-derived PDGF-C and hepatic stellate cell-derived PAK-2. Bandapalli OR, Macher-Goeppinger S, Schirmacher P, Brand K, Clin Exp Metastasis 2012 29 409 417
268. PDGF-D is a potent transforming and angiogenic growth factor. Li H, Fredriksson L, Li X, Eriksson U, Oncogene 2003 22 1501 1510 (Pubitemid 36390599)
269. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Furuhashi M, Sjöblom T, Abramsson A, Ellingsen J, Micke P, Li H, Bergsten-Folestad E, Eriksson U, Heuchel R, Betsholtz C, et al. Cancer Res 2004 64 2725 2733 (Pubitemid 38500608)
270. Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival. Hägglöf C, Hammarsten P, Josefsson A, Stattin P, Paulsson J, Bergh A, Östman A, PLoS One 2010 5 10747
271. Prognostic significance of stromal platelet-derived growth factor β-receptor expression in human breast cancer. Paulsson J, Sjöblom T, Micke P, Pontén F, Landberg G, Heldin C-H, Bergh J, Brennan DJ, Jirström K, Östman A, Am J Pathol 2009 175 334 341
272. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Fidler IJ, Am J Pathol 2006 169 2054 2065 (Pubitemid 351181965)
273. PDGFRβ expression in tumor stroma of pancreatic adenocarcinoma as a reliable prognostic marker. Yuzawa S, Kano MR, Einama T, Nishihara H, Med Oncol 2012 29 2824 2830
274. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Pietras K, Östman A, Sjöquist M, Buchdunger E, Reed RK, Heldin C-H, Rubin K, Cancer Res 2001 61 2929 2934 (Pubitemid 32691937)
275. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Pietras K, Rubin K, Sjöblom T, Buchdunger E, Sjöquist M, Heldin C-H, Östman A, Cancer Res 2002 62 5476 5484
276. Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B. Falcon BL, Pietras K, Chou J, Chen D, Sennino B, Hanahan D, McDonald DM, Am J Pathol 2011 178 2920 2930
277. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK, Cancer Res 2004 64 3731 3736 (Pubitemid 38697278)
278. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, et al. Nat Med 2004 10 145 147 (Pubitemid 38524883)
279. Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma. Kłosowska-Wardȩga A, Hasumi Y, Burmakin M, Åhgren A, Stuhr L, Moen I, Reed RK, Rubin K, Hellberg C, Heldin C-H, PLoS One 2009 4 8149
280. Stromal platelet-derived growth factor receptor (PDGFR) provides a therapeutic target independent of tumor cell PDGFR expression in lung cancer xenografts. Gerber DE, Gupta P, Dellinger MT, Toombs JE, Peyton M, Duignan I, Malaby J, Bailey T, Burns C, Brekken RA, Loizos N, Mol Cancer Ther 2012 11 2473 2482
281. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells. Kinoshita K, Nakagawa K, Hamada J, Hida Y, Tada M, Kondo S, Moriuchi T, Int J Oncol 2010 37 869 877
282. PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis. Catena R, Luis-Ravelo D, Anton I, Zandueta C, Salazar-Colocho P, Larzabal L, Calvo A, Lecanda F, Cancer Res 2010 71 164 174
283. Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer. Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Onoyama M, Ohnishi M, Ohara E, Higashi Y, Tanaka S, Yasui W, Chayama K, Int J Cancer 2013 132 813 823